Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for RCEL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 1999. Start Trial.
Date Value
December 31, 2025 -31.20M
December 31, 2024 -48.94M
December 31, 2023 -38.01M
December 31, 2022 -19.09M
June 30, 2021 -25.90M
June 30, 2020 -22.75M
June 30, 2019 -19.66M
June 30, 2018 -12.68M
June 30, 2017 -6.454M
June 30, 2016 -5.446M
June 30, 2015 -5.337M
June 30, 2014 -6.357M
June 30, 2013 -7.438M
June 30, 2012 -4.399M
Date Value
June 30, 2011 -2.883M
June 30, 2010 -1.425M
June 30, 2009 -3.448M
June 30, 2008 -3.302M
June 30, 2007 -7.044M
June 30, 2006 -7.346M
June 30, 2005 -9.202M
June 30, 2004 -4.283M
June 30, 2003 -0.5755M
December 31, 2002 -1.032M
December 31, 2001 -0.2996M
December 31, 2000 -0.4712M
December 31, 1999 -0.6204M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Halozyme Therapeutics, Inc. 651.56M
Iovance Biotherapeutics, Inc. -302.41M
Editas Medicine, Inc. -165.24M
Arcus Biosciences, Inc. -482.00M
Recursion Pharmaceuticals, Inc. -371.81M